SCHEMBL15327909

SCHEMBL15327909

COc1cc(F)c(C(=O)NC(N)=O)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.48
ALDH1A1 P00352 2/20 0.42
AURKA O14965 1/20 0.41
AURKB Q96GD4 1/20 0.41
RPS6KB1 P23443 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
PLAU P00749 2/20 0.40
HDAC1 Q13547 2/20 0.40
GPR35 Q9HC97 1/20 0.40
NPC1 O15118 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
GAA P10253 3/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20257271 0.80 ALDH1A1 (0.49) RAB9AALDH1A1TAAR1HDAC1GPR35
SCHEMBL9241705 0.80 TAAR1 (0.52) RAB9AALDH1A1TAAR1HDAC1SMN1; SMN2
SCHEMBL15327994 0.79 CPS1 (0.54) RAB9AALDH1A1NPC1GAAKMT2A
SCHEMBL15328092 0.77 GAA (0.54) RAB9AALDH1A1PLAUNPC1SMN1; SMN2
SCHEMBL8017091 0.76 CYP3A4 (0.55) RAB9AALDH1A1TAAR1HDAC1GAA
SCHEMBL15328160 0.75 ALDH1A1 (0.51) RAB9AALDH1A1TAAR1PLAUHDAC1
Carbamic Acid SCHEMBL25384958 0.74 TAAR1 (0.37) RAB9AALDH1A1TAAR1PLAUHDAC1
SCHEMBL2382494 0.74 CYP3A4 (0.53) RAB9AALDH1A1TAAR1HDAC1NPC1
SCHEMBL1646977 0.74 POLB (0.45) RAB9AALDH1A1TAAR1GPR35GAA
SCHEMBL27675595 0.72 KMT2A (0.62) RAB9AALDH1A1AURKAAURKBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP claimed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US claimed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US claimed
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ING2, CDK2, MAP3K20 RAB9A 2739/4885ALDH1A1 3369/4885AURKA 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.